DOP002: Vedolizumab treatment persistence up to 3 years: post hoc analysis in vedolizumab-naïve patients from the GEMINI LTS studyECCO '18 Vienna
2018
DOP003: Ustekinumab induces clinical and biological remission in biologic refractory Crohn’s disease patients: A real-world belgian cohort studyECCO '18 Vienna
2018
DOP004: Long-term safety of adalimumab in patients with moderate-to-severe ulcerative colitis: Interim results of a non-interventional registry, LEGACYECCO '18 Vienna
2018
DOP005: Safety of vedolizumab in patients naïve to treatment with TNF antagonists compared with patients with prior use of TNF antagonistsECCO '18 Vienna
2018
DOP006: A multicentre cohort study to assess the safety of vedolizumab for inflammatory bowel diseaseECCO '18 Vienna
2018
DOP007: Efficacy of vedolizumab induction therapy on clinical and endoscopic activity in patients with anti-tumour necrosis factor alpha-resistant inflammatory bowel diseaseECCO '18 Vienna
2018
DOP008: Safety of adalimumab in children and adolescents with moderate-to-severe Crohn’s disease: interim results of the CAPE registryECCO '18 Vienna
2018
DOP010: Activating PIK3CD mutations cause severe intestinal lymphonodular hyperplasia and an IBD-like phenotypeECCO '18 Vienna
2018
DOP011: Genotype–phenotype association analysis of inflammatory bowel disease in 6395 East Asian subjects: results from the international IBD Genetics ConsortiumECCO '18 Vienna
2018
DOP012: Disease demarcation in ulcerative colitis is associated with different patterns of gene expressionECCO '18 Vienna
2018
DOP013: An IBD-associated variant in PTPN2 promotes inflammatory responses but enhances the anti-inflammatory effect of spermidineECCO '18 Vienna
2018
DOP014: Impact of genetic variation on gene and protein expression in Crohn’s diseaseECCO '18 Vienna
2018
DOP015: Dysregulation of cell-type-specific long ncRNA in the ileum of treatment naïve early onset Crohn diseaseECCO '18 Vienna
2018
DOP016: Metagenomic analysis of intestinal mucosa revealed an IBD-specific shift in the eukaryotic gut virome composition at early stages of gut inflammationECCO '18 Vienna
2018
DOP017: Increased intestinal aryl hydrocarbon receptor expression and pathway sensitivity in Crohn’s diseaseECCO '18 Vienna
2018
DOP018: Baseline ILC1 distribution in blood predicts response to ustekinumab in patients with refractory Crohn’s diseaseECCO '18 Vienna
2018
DOP019: Immunomodulators reduce the risk of surgery and hospitalisation in Crohn’s disease in a prospective European population-based inception cohort: the Epi-IBD cohortECCO '18 Vienna
2018